Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

FOSTER CITY, Calif., November 08, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

November 06, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the ...